A hope was supposed to come in 2019 after the Food and Drug Administration (FDA) approved Ruxolitinib (RUX), a JAK1/2 inhibitor, for therapy of SR-aGVHD in adult and pediatric patients > 12 years [4]. Approval was based on favourable results of REACH2 clinical trial in which RUX showed the advantage over other well-known immunosuppressive therapies. Promising response rate to RUX at day 28 was 62.3% when compared with 39.4% in control group (p < 0.001) [5].
Obviously Reach2 failed to demonstrate true response rates.
banter and General Discussion, page-11080
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.14 |
Change
0.010(0.89%) |
Mkt cap ! $1.307B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.18 | $1.13 | $2.969M | 2.583M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 7870 | $1.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.15 | 9510 | 8 |
View Market Depth
| Last trade - 13.01pm 30/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |